Furthering the clinical development of navicixizumab in advanced epithelial ovarian cancer patients with a population pharmacokinetic model and exploratory exposure-safety-efficacy response analyses

Authors: Roberts JK, Barcomb H, Dykstra, K, Culm K
Conference: Society of Gynecologic Oncology (SGO)
Keywords: angiogenesis, anti-angiogenic antibody, Navicixizumab, vascular endothelial growth factor, VEGF
Division: Clinical Pharmacology and Pharmacometrics (CPP)

Navicixizumab: Strategically Designed for Efficacy and Safety

•Navicixizumab is a first-in-class, bispecific, anti-angiogenic antibody to vascular endothelial growth factor (VEGF) and delta-like ligand 4 (DLL4) in the Notch pathway
•Designed to overcome VEGF resistance and more potent than targeting either DLL4 or VEGF alone
•Designed to retain potent antitumor effects while reducing risks associated with DLL4 inhibition
•Designed to downregulate DDL4-Notch signaling in tumors and both Notch and VEGF pathways in angiogenesis

By, Jessica K Roberts, Heather Barcomb, Kevin Dykstra, and Kerry Culm.

Poster presented at the Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer; March 18 – 21, 2022; Phoenix, AZ.